Neurocognitive changes in a patient receiving esketamine for treatment-resistant depression.
JAAPA : official journal of the American Academy of Physician Assistants September 1, 2024 Carolyn F Kundert, Robert M Sobule, Muaid Ithman 1 citation
Esketamine, approved in 2019 as a rapid-acting intranasal spray for treatment-resistant depression, is self-administered under clinical supervision and generally well tolerated, with mild, temporary, and dose-dependent adverse reactions that improve over time. Although difficulty remembering or thinking is listed as a possible adverse reaction, neurocognitive evaluation is not part of initial patient assessment. This case report describes a patient whose neurocognitive symptoms worsened with esketamine treatment, leading to discontinuation of the therapy.